J&J vaccine adds to COVID-19 armoury, includes South African variant - Reuters

2:34pm PST - January 29th, 2021    novavax stock - Reuters

Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants, giving health officials another weapon to tackle the pandemic.